Actively Recruiting

Phase 3
Age: 60Years +
All Genders
ID06989697

Impact of Cilostazol and Ginkgo Leaf Extract on Cognitive Function in Elderly Patients With Type 2 Diabetes

Led by Seoul National University Bundang Hospital · Updated on 2025-05-25

80

Participants Needed

1

Research Sites

25 weeks

Total Duration

On this page

Sponsors

S

Seoul National University Bundang Hospital

Lead Sponsor

S

SK Chemicals Co., Ltd.

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are investigating the potential cognitive benefits of a combination therapy using cilostazol (200 mg) and ginkgo biloba extract (160 mg) in older adults with type 2 diabetes mellitus. This study is a phase 3, randomized trial focusing on whether this treatment can help prevent or reduce cognitive decline, given the higher risk of dementia in people with diabetes. The study aims to provide important data for future treatments targeting cognitive impairment in this population. Participants will be randomly assigned to receive either the combination therapy or a placebo. The active treatment involves taking a sustained-release tablet once daily containing both cilostazol and ginkgo biloba extract. The placebo group will take a similar-looking tablet without the active ingredients. This treatment phase lasts for 6 months. During the study, participants will undergo regular assessments including cognitive tests such as the Mini-Mental State Examination (MMSE), Korean Dementia Screening Questionnaire, Montreal Cognitive Assessment, and Global Deterioration Scale. Health-related quality of life will also be measured using the Short Form-36 survey. Researchers will monitor changes in these measures from the start to the end of the 6-month period to evaluate cognitive improvement and safety.

CONDITIONS

Brief Title

Cilostazol-Ginkgo for Cognitive Function in Elderly Diabetes

Who Can Participate

Age: 60Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients diagnosed with type 2 diabetes mellitus
  • Adults aged 60 years or older
  • Patients with a Mini-Mental State Examination (MMSE) score between 24 and 28 within the past 3 months
Not Eligible

You will not qualify if you...

  • Patients with type 1 diabetes mellitus, diabetic ketoacidosis, or diabetic coma or precoma
  • Patients with poorly controlled blood glucose (HbA1c > 10.0%)
  • Patients with an MMSE score below 24
  • Patients diagnosed with dementia (e.g., Alzheimer's disease)
  • Patients with suspected cognitive impairment due to other causes
  • Patients requiring antiplatelet or anticoagulant therapy other than the investigational product
  • Patients with thyroid dysfunction requiring treatment (i.e., abnormal TSH levels)
  • Patients with severe depression
  • Patients with severe infections, recent surgery (perioperative status), or major trauma
  • Patients with pituitary or adrenal insufficiency
  • Patients with other medical conditions requiring hospitalization
  • Patients with a history of alcohol or drug abuse within 1 year prior to screening
  • Patients with a history of taking medications that may affect cognitive function within 3 months prior to screening
  • Patients deemed by the investigator to be otherwise unsuitable for study participation

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - 6 months

Participants receive daily oral tablets of either cilostazol with ginkgo biloba extract or placebo to assess effects on cognitive function.

Monthly visits for 6 months

Trial Site Locations

Total: 1 location

1

Seoul National University Bundang Hospital

Seongnam-si, South Korea

Actively Recruiting

Loading map...

Research Team

S

Soo Lim Dr., MD PhD

M

Minji Sohn Dr, PhD

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

SUPPORTIVE_CARE

Number of Arms

2

Similar Trials

Associations Between Dietary Intake and Cardiometabolic and ...

Cardiometabolic Risk Factors

Actively Recruiting

1 location

Understanding the Cognitive and Brain Health Effects of Incr...

Dietary Intervention

Actively Recruiting

1 location

Red Blood Cell Transfusion in ECMO - A Feasibility Trial

Blood Loss Anemia

Actively Recruiting

2 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here